Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Infectious Disease

Articles with lock require a GLG News subscription
Posted February 27, 2008
Promising phase I/II data in HIV with once-daily NNRTI from Idenix
Analysis of: Promising phase I/II data in HIV with once-daily NNRTI from Idenix | www.pipelinereview.com
Author: GLG Member Program Contributor
Etravirine is a novel and very promising NNRTI since it has not cross-resistance with the existing NNRTIs (efavirenz and nevirapine), and also encompasses excellent efficacy, convenience, and a good tolerability.
Posted February 26, 2008
Promising phase I/II data in HIV with once-daily NNRTI from Idenix
Analysis of: Promising phase I/II data in HIV with once-daily NNRTI from Idenix | www.pipelinereview.com
Author: GLG Member Program Contributor
A new NNRTI that overcomes class resistance and with a low threshold for development of resistance will be a useful addition to our antiretroviral armamentarium.
Posted February 11, 2008
Promising phase I/II data in HIV with once-daily NNRTI from Idenix
Analysis of: Promising phase I/II data in HIV with once-daily NNRTI from Idenix | www.pipelinereview.com
Author: GLG Member Program Contributor
HIV therapy must be the strongest and the most safe therapy ; NNRTI are the key drugs for this kind of therapy. When you,doctor,begin a  naive HIV therapy, you must think that your patient should be treated for a very long time , maybe for a whole life period ; it'simportant...
Posted February 7, 2008
CDC: Too few adults get their vaccines
Analysis of:  CDC: Too few adults get their vaccines | news.yahoo.com
Author: GLG Member Program Contributor
Vaccines have been shown again and again to be cost-effective tools. Fortunately, pediatric vaccines are generally given, since the schools enforce the requirements. But adults would benefit as well.
Posted February 6, 2008
CDC: Too few adults get their vaccines
Analysis of:  CDC: Too few adults get their vaccines | news.yahoo.com
Author: GLG Member Program Contributor
Three Comments Come to Mind: 1) New vaccines are not well publicized so many people don't know what is being developed. 2) Vaccine development has not been historically profitable, so many pharma companies still have sour tastes in their mouths. Biotech companies are able to find ways to make new vaccines...
Posted February 1, 2008
CDC: Too few adults get their vaccines
Analysis of:  CDC: Too few adults get their vaccines | news.yahoo.com
Author: GLG Member Program Contributor
Vaccines do not get the PR that ED drugs do.Perhaps if they did  the public would understand their importance. TV shows that propose that vaccines are harmful clearly do not help.
Posted January 30, 2008
Human Genome Sciences Modifies Dosing In Achieve Trials of Albuferon(R)
Analysis of: Human Genome Sciences Modifies Dosing In Achieve Trials of Albuferon(R) | www.pipelinereview.com
Author: GLG Member Program Contributor
In the two large phase 3 registration trials of albinterferon alfa-2b (Albuferon, Human Genome Sciences), called ACHIEVE-1 and ACHIEVE-2/3, several patients in the arm using Albuferon 1200 mcg per 2 weeks + RBV were found to have serious pulmonry adverse events.  Such serious events were not...
Posted January 25, 2008
CDC: Too few adults get their vaccines
Analysis of:  CDC: Too few adults get their vaccines | news.yahoo.com
Author: GLG Member Program Contributor
It is disappointing that Medicare does not pay for well exams where vaccines like this would be given.  It is unfortunate that in an attempt by medicare to save money, they are probably losing money.  It is at the annual well exam where I counsel patients on the vaccinations that they should...
Posted January 17, 2008
Phase II Study Shows that Nitazoxanide Significantly Improves Response to Standard of Care in Patients with Chronic Hepatitis C
Analysis of: Phase II Study Shows that Nitazoxanide Significantly Improves Response to Standard of Care in Patients with Chronic Hepatitis C | www.romark.com
Author: GLG Member Program Contributor
A phase 2 study in Egypt of hepatitis C genotype 4 showed that the viral cure or SVR rate (here actually SVR12 = %HCV RNA negative at post-Rx week 12, real SVR is at week 24) is much improved when nitazoxanide is added to standard therapy.  SVR12 was 79% in nitazoxanide + Pegasys + ribavirin...
Posted January 17, 2008
InterMune Announces Continuing Progress on ITMN-191 (R7227)
Analysis of: InterMune Announces Continuing Progress on ITMN-191 (R7227) | phx.corporate-ir.net
Author: GLG Member Program Contributor
In the phase 1a (single ascending dose, SAD) trial, ITMN-191 was found to be safe in the first doses tested, and more cohorts will be tested with higher doses.  Details of the study will be presented later in quarter 1 of 2008.  Multiple ascending doses (MAD) in a 2-week monotherapy phase...
Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 Next31 to 40 of 210

GLG News: What Experts Think Is Important





Analytics